Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 06, 2016 8:57 AM ET


Company Overview of Novartis Oncology

Company Overview

Novartis Oncology engages in the discovery and development of therapies and medicines for cancer. It focuses on the research platforms spanning discoveries in signal transduction inhibition, cytotoxic agents, antiangiogenesis, cell cyle/apoptosis, iron chelation, metastases, and hormone therapy. The company’s products include EXJADE, a drug indicated for the treatment of chronic iron overload due to frequent blood transfusions; Femara letrozole tablets indicated for the treatment of breast cancer in postmenopausal women; Glivec, a cancer treatment indicated for adult and pediatric patients with diagnosed Ph+ chronic myeloid leukemia; and Sandostatin LAR octreotide/IM injection for the treatm...

One Health Plaza

East Hanover, NJ 07936 1080

United States



Key Executives for Novartis Oncology

Global Head of Oncology Development and Executive Vice President
Vice President and Global Head of NIBR Oncology Research
Compensation as of Fiscal Year 2015.

Novartis Oncology Key Developments

Novartis Oncology Announces Sales Results for the First Half of 2015

Novartis Oncology announced sales results for the first half of 2015. For the period, sales grew 30%.

Novartis Oncology Presents at BIO-Europe 2014, Nov-03-2014 02:45 PM

Novartis Oncology Presents at BIO-Europe 2014, Nov-03-2014 02:45 PM. Venue: Portalhaus Messe Frankfurt, Strasse der Nationen, 60327 Frankfurt, Germany. Speakers: Anne Altmeyer, VP, Business Development and Licensing.

Novartis Oncology Announces Executive Changes

Novartis AG said that it has appointed a senior executive of Merck & Co. (MRK), Bruno Strigini, as president of its oncology business, Novartis Oncology. His appointment is with immediate effect. Novartis said in mid-January that Herve Hoppenot resigned as president of Novartis Oncology to pursue a career opportunity outside of the organization. At that time, the company appointed Alessandro Riva as president of Novartis Oncology on an interim basis, until a successor was found for Hoppenot who has led the oncology business since 2010. Strigini most recently served as president for Merck's Europe/Canada operations. He has 25 years of experience in pharmaceuticals, animal health, OTC and vaccines, having led in both international and local roles. Strigini is a member of the Executive Committee for the European Federation of Pharmaceutical Industries & Associations or EFPIA, as well as a member of the Academie Nationale de Pharmacie in France.

Similar Private Companies By Industry

Company Name Region
Mt. Cook Pharma, Inc. United States
Pops Edibles United States
TOKU-E Corporation United States
Valeritas, Inc. United States
Sanofi-Topaz Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Novartis Oncology, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at